ArticleBMC research notes2018

Response to flutamide, as second-line therapy after bicalutamide, predicts efficacy of abiraterone, not that of enzalutamide.

Yasushi Nakai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.